{
  "_metadata": {
    "version": "2.0",
    "ticker": "ARWR",
    "asset_name": "aro_inhbe",
    "extracted_from": "ARWR Investment Thesis, Company Presentations",
    "extraction_date": "2026-02-05",
    "analyst_reviewed": true
  },
  "asset": {
    "name": "ARO-INHBE",
    "alternate_names": [],
    "company": "Arrowhead Pharmaceuticals",
    "ticker": "ARWR",
    "stage": "Phase 1/2",
    "modality": "RNAi (siRNA)",
    "ownership": "Wholly-owned",
    "one_liner": "Novel obesity approach with 6-9% weight loss, quarterly dosing, and no GI side effects"
  },
  "target": {
    "name": "INHBE",
    "full_name": "Inhibin Beta E",
    "class": "TGF-beta superfamily ligand",
    "pathway": "Activin E / ALK7 signaling in adipose tissue",
    "biology": {
      "simple_explanation": "INHBE forms activin E, which signals through the ALK7 receptor in adipose tissue to promote fat accumulation. By silencing INHBE, ARO-INHBE blocks activin E production, shifting energy balance toward fat oxidation and weight loss.",
      "pathway_detail": "INHBE is secreted by the liver and forms activin E homodimers. Activin E binds ALK7 (ACVR1C) on adipocytes, activating SMAD signaling that promotes lipid storage and inhibits lipolysis.",
      "downstream_effects": [
        "Reduced activin E signaling",
        "Increased fat oxidation",
        "6-9% weight loss in Phase 1"
      ]
    },
    "why_good_target": {
      "genetic_validation": {
        "loss_of_function": "INHBE LoF mutations associated with lower BMI and reduced obesity risk"
      },
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    }
  },
  "mechanism": {
    "type": "RNAi (siRNA) via TRiM platform",
    "delivery": "GalNAc-conjugated for hepatocyte targeting",
    "how_it_works": "ARO-INHBE silences INHBE mRNA in hepatocytes, reducing production of activin E. Without activin E signaling through ALK7, adipose tissue shifts from fat storage to fat oxidation, resulting in weight loss.",
    "differentiation_vs_glp1": [
      "Quarterly dosing vs weekly for GLP-1s",
      "No GI side effects (nausea, vomiting) unlike GLP-1s",
      "Novel mechanism orthogonal to incretin pathway"
    ],
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "indications": {
    "lead": {
      "name": "Obesity",
      "patient_population": "~100M US adults with obesity",
      "status": "Phase 1/2",
      "rationale": "Massive market with high unmet need for non-GLP-1 options"
    },
    "expansion": [
      {
        "name": "Metabolic Dysfunction",
        "status": "Early evaluation",
        "rationale": "Metabolic effects beyond weight loss"
      }
    ],
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "clinical_data": {
    "phase1_data": {
      "trial_name": "ARO-INHBE Phase 1/2",
      "nct_id": "NCT06700538",
      "results": {
        "weight_loss": "6-9%",
        "gi_side_effects": "None reported (unlike GLP-1s)",
        "dosing": "Quarterly (Q12W)",
        "interpretation": "Proof of concept established; differentiated safety profile"
      },
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    },
    "ongoing_trials": [
      {
        "trial_name": "ARO-INHBE Phase 1/2",
        "nct_id": "NCT06700538",
        "phase": "Phase 1/2",
        "indication": "Obesity",
        "status": "Recruiting"
      }
    ]
  },
  "investment_analysis": {
    "bull_case": [
      {
        "point": "Novel genetically-validated obesity target",
        "evidence": "INHBE LoF mutations associated with lower BMI",
        "confidence": "High"
      },
      {
        "point": "Differentiated profile vs GLP-1s",
        "evidence": "Quarterly dosing, no GI side effects",
        "confidence": "Medium - early data"
      },
      {
        "point": "ARWR retains full rights",
        "evidence": "Wholly-owned program, no partner economics",
        "confidence": "High"
      },
      {
        "point": "Massive market opportunity",
        "evidence": "Obesity is $50B+ market opportunity",
        "confidence": "High if efficacy competitive"
      }
    ],
    "bear_case": [
      {
        "point": "GLP-1s achieving 15-25% weight loss are becoming standard of care",
        "evidence": "Wegovy: 15-17%, Zepbound: 20-25%",
        "counter_argument": "Different mechanism, potential for combination"
      },
      {
        "point": "6-9% weight loss may not be competitive",
        "evidence": "Less than half of GLP-1 efficacy",
        "counter_argument": "May improve with optimization; quarterly dosing and no GI AEs differentiate"
      },
      {
        "point": "Mechanism less understood than GLP-1",
        "evidence": "Newer pathway with less clinical validation",
        "counter_argument": "Genetic validation provides foundation"
      }
    ],
    "key_debates": [
      {
        "question": "Can ARO-INHBE achieve >15% weight loss to compete with GLP-1s?",
        "bull_view": "Dose optimization may improve efficacy; combination potential",
        "bear_view": "Mechanism may have ceiling effect below GLP-1 efficacy",
        "what_resolves_it": "Phase 2 dose-response data"
      }
    ]
  },
  "competitive_landscape": [
    {
      "competitor": "Semaglutide (Wegovy)",
      "company": "Novo Nordisk",
      "mechanism": "GLP-1 agonist",
      "stage": "Approved",
      "efficacy": "15-17% weight loss",
      "differentiation": "ARO-INHBE is quarterly vs weekly, no GI side effects"
    },
    {
      "competitor": "Tirzepatide (Zepbound)",
      "company": "Eli Lilly",
      "mechanism": "GLP-1/GIP dual agonist",
      "stage": "Approved",
      "efficacy": "20-25% weight loss",
      "differentiation": "Tirzepatide best-in-class efficacy; ARO-INHBE offers different mechanism"
    }
  ],
  "catalysts": [
    {
      "event": "Phase 1/2 dose-expansion data",
      "timing": "2026",
      "importance": "High",
      "what_to_watch": "Weight loss magnitude, dose-response, safety"
    }
  ],
  "sources": [
    {
      "id": "arwr_thesis_2026",
      "title": "ARWR Investment Thesis",
      "type": "Internal Analysis",
      "date": "2026-02-02"
    },
    {
      "id": "clinicaltrials",
      "title": "ClinicalTrials.gov",
      "type": "Clinical Trial Registry",
      "url": "https://clinicaltrials.gov/api/v2/studies"
    }
  ]
}
